32779-38-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-iodopyrimidine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its halo-substituted pyrimidine core is a common structural motif found in many bioactive molecules, including antiviral, anticancer, and antimicrobial agents. The presence of the chlorine and iodine atoms enables further functionalization and optimization of the synthesized compounds, enhancing their therapeutic properties and selectivity.
Used in Chemical Research:
In the field of chemical research, 2-Chloro-5-iodopyrimidine serves as a versatile building block for the development of novel organic compounds. Its reactivity allows for a wide range of chemical transformations, such as cross-coupling reactions, nucleophilic substitutions, and electrophilic aromatic substitutions. These reactions enable the synthesis of diverse pyrimidine-based derivatives with potential applications in various fields, including materials science, agrochemistry, and medicinal chemistry.
Used in Synthesis of Bioactive Molecules:
2-Chloro-5-iodopyrimidine is employed as a starting material for the synthesis of bioactive molecules with potential applications in biology and medicine. Its unique structural features and reactivity make it an attractive candidate for the development of new drugs and therapeutic agents. The synthesized bioactive molecules can be further evaluated for their biological activities, such as enzyme inhibition, receptor binding, and modulation of cellular signaling pathways, leading to the discovery of novel therapeutic agents for various diseases and conditions.

InChI:InChI=1/C4H2ClIN2/c5-3-1-7-4(6)8-2-3/h1-2H

Upstream product

• 79387-69-2 5-iodo-2-hydroxypyrimidine 
• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 1445-39-2 2-amino-5-iodopyrimidine 

Downstream Products

• 83173-31-3 3-Chloro-4-(5-iodo-pyrimidin-2-yloxy)-phenylamine 
• 109230-58-2 2-(4-((5-Iodo-2-pyrimidinyl)oxy)phenoxy)-N-(4-(trifluoromethoxy)phenyl)propanamide 
• 95847-41-9 5-iodo-2-(piperazin-1-yl)pyrimidine 
• 1083329-25-2 2,5-dibenzyloxypyrimidine 
• 1083329-27-4 2-benzyloxy-5-iodopyrimidine 
• 1364767-36-1 2-[4-(2-chloro-pyrimidin-5-ylethynyl)-phenyl]-N-ethyl-propionamide 
• 1353777-14-6 (S)-cyclopropanecarboxylic acid (1-{4-[1-(5-iodopyrimidin-2-yl)piperidin-4-yl]phenyl}ethyl)amide 
• 1363436-28-5 N-(1-(4-((2-(sec-Butylamino)pyrimidin-5-yl)ethynyl)phenyl)propan-2-yl)acetamide 
• 1404113-79-6 2-chloro-5-(4-fluoro-phenylethynyl)-pyrimidine 
• 1453211-47-6 5-iodo-N-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine 
• 101803-06-9 5-iodo-2-methoxypyrimidine 

Relevant academic research and scientific papers

Intermolecular contacts in the crystal structures of specifically varied halogen and protonic group substituted azines

A series of azines featuring differently halogen and protic group substituted pyridine, pyrimidine and pyridazine compounds have been synthesized and studied in terms of their crystal structures in order to develop a better understanding of the links between structural conditions and molecular packing behavior. Complemented by the structure results of related compounds known from the literature, intermolecular contact relationships connected to the present substance types were found, having potential use in future crystal engineering of similar compounds. This primarily involves the formation of N?I contacts aside from specific halogen?halogen and hydrogen bond type interactions.

Nickel-Catalyzed Asymmetric Reductive Cross-Coupling between Heteroaryl Iodides and α-Chloronitriles

A Ni-catalyzed asymmetric reductive cross-coupling of heteroaryl iodides and α-chloronitriles has been developed. This method furnishes enantioenriched α,α-disubstituted nitriles from simple organohalide building blocks. The reaction tolerates a variety of heterocyclic coupling partners, including pyridines, pyrimidines, quinolines, thiophenes, and piperidines. The reaction proceeds under mild conditions at room temperature and precludes the need to pregenerate organometallic nucleophiles.

Synthesis and Structural Characterization of Ethynylene-Bridged Bisazines Featuring Various α-Substitution

A series of bispyridines and bispyrimidines 1a, 1b, 1c, 1d, 1e showing the heterocycles attached to both ends of an ethynylene unit and being α-substituted with chloro, tert-butylthio, and methoxy groups have been synthesized via cross-coupling technique and their crystal structures studied by X-ray diffraction analysis. Supramolecular interactions of C-H···N and π···π stacking type were found to largely dominate the structures according to the compound species. A trial was given to deduce the markedly differing temperatures of melting among the compounds from special features of the crystal structures.

TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS

Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R21, T1, T2, T3 and T4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

A simple Cu-catalyzed coupling approach to substituted 3-pyridinol and 5-pyrimidinol antioxidants

(Chemical Equation Presented) A convenient approach to 3-pyridinols and 5-pyrimidinols via a two-step Cu-catalyzed benzyloxylation/catalytic hydrogenation sequence is presented. The corresponding 3-pyridinamines and 5-pyrimidinamines can be prepared in an analogous sequence utilizing benzylamine in lieu of benzyl alcohol. The radical-scavenging ability of these derivatives are preliminarily explored and reveal that the increased acidities of the pyridinols and pyrimidinols render them susceptible to more significant kinetic solvent effects when compared to phenols.

Development of a concise scaleable synthesis of 2-chloro-5-(pyridin-2-yl) pyrimidine via a Negishi cross-coupling

A practical and scaleable synthesis of 2-chloro-5-(pyridin-2-yl) pyrimidine, an intermediate in the synthesis of a selective PDE-V inhibitor, was developed. A Negishi cross-coupling between the in situ prepared 2-pyridylzinc chloride and 5-iodo-2-chloropyrimidine catalyzed by Pd(PPh3)4 afforded the product in one step. Development of a convenient purification did away with the necessity of chromatography, allowing the preparation of the product on kilogram scale.

Derivatives of (pyrimidyloxy)phenoxy-alkanecarboxylic acid and herbicidal compositions thereof

A compound of general formula I: STR1 wherein A, B, D, E, and V are independently chosen from hydrogen, halogen, nitro, cyano, thiocyano, amino, alkyl, alkoxy, alkylthio, alkenyl, cycloalkyl, carbalkoxy, phenyl, phenoxy or phenylthio; R1 and R2 are independently hydrogen, alkyl, alkenyl, alkanoyl, or R1 and R2 together are alkylidene; W is carboxy or a functional derivative thereof or CH2 Z wherein Z is halogen, hydroxy, alkoxy, alkylthio, formyl or amino; and X and Y are oxygen or sulfur.